|
ev3 Stage: Growth Date of Investment: 2000 Web Site : http://www.ev3.net Stock Symbol : NASDAQ: EVVV |
 |
ev3, headquartered in Plymouth, Minnesota, is a leading global endovascular device company focused on the treatment of peripheral vascular and neurovascular disease. Since ev3's founding in 2000, Warburg Pincus has fostered the Company's product development strategy by funding internal development programs and strategic acquisitions. Warburg Pincus has also helped recruit a roster of highly talented managers with extensive experience in all aspects of the interventional devices business, including sales and marketing, clinical trials, regulatory approvals and research and development. On June 16, 2005, ev3 completed its initial public offering, raising $120 million in net proceeds. On April 20, 2007, the Company successfully completed a $166 million follow-on offering. In October 2007 ev3 acquired Fox Hollow Technologies, an innovator in atherectomy devices for the treatment of peripheral vascular disease. In June 2009, ev3 acquired Chestnut Medical Technologies, a private company focused on developing minimally invasive neurovascular therapies, including the Pipeline Embolization Device, a novel treatment for aneurysms.
